# XOMA Royalty

Type: Company (XOMA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/xoma-royalty
Canonical HTML page: https://getbiobrief.com/entity/xoma-royalty

## Timeline

- **2026-03-19**: Earnings Call — Management hosts a conference call to discuss 2025 performance and 2026 outlook.
- **2026-03-18**: Financial Reporting — XOMA files Q4 and Full Year 2025 financial results with the SEC.
- **2026-02-02**: Asset Acquisition — Completion of a significant acquisition of royalty rights from a clinical-stage partner.
- **2026-01-12**: Strategic Disclosure — XOMA issues Regulation FD disclosure regarding portfolio updates.

## Recent coverage (1 stories)

### XOMA Royalty Reports Q4 Results as Portfolio Scaling Drives Long-Term Value
2026-03-19 15:43:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Full story: https://getbiobrief.com/story/xoma-royalty-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.